Northern Trust Corp Purchases 29,768 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Northern Trust Corp raised its holdings in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 368,088 shares of the medical device company's stock after acquiring an additional 29,768 shares during the quarter. Northern Trust Corp owned about 0.96% of Orthofix Medical worth $6,427,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in OFIX. R Squared Ltd bought a new position in shares of Orthofix Medical during the 4th quarter valued at $50,000. KLP Kapitalforvaltning AS acquired a new position in Orthofix Medical during the fourth quarter worth $112,000. Tower Research Capital LLC TRC raised its holdings in Orthofix Medical by 120.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock valued at $148,000 after buying an additional 4,627 shares in the last quarter. XTX Topco Ltd bought a new position in Orthofix Medical during the fourth quarter valued at about $234,000. Finally, Inceptionr LLC acquired a new stake in shares of Orthofix Medical in the fourth quarter worth about $279,000. 89.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on OFIX shares. Wall Street Zen lowered Orthofix Medical from a "buy" rating to a "hold" rating in a report on Wednesday, May 7th. Roth Mkm reissued a "buy" rating and set a $22.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th.

Orthofix Medical Stock Performance

OFIX stock traded down $0.13 during trading on Friday, reaching $11.10. 572,966 shares of the stock were exchanged, compared to its average volume of 267,576. Orthofix Medical Inc. has a twelve month low of $10.50 and a twelve month high of $20.73. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $433.14 million, a P/E ratio of -3.55 and a beta of 0.87. The stock has a 50 day simple moving average of $13.89 and a 200-day simple moving average of $16.57.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, CEO Massimo Calafiore purchased 10,000 shares of the stock in a transaction on Friday, May 9th. The shares were purchased at an average price of $12.54 per share, with a total value of $125,400.00. Following the acquisition, the chief executive officer now directly owns 234,603 shares of the company's stock, valued at $2,941,921.62. This represents a 4.45% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Engine Capital Management, Lp acquired 100,000 shares of Orthofix Medical stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $12.31 per share, with a total value of $1,231,000.00. Following the completion of the acquisition, the insider now directly owns 3,544,807 shares in the company, valued at $43,636,574.17. This trade represents a 2.90% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 8,475 shares of company stock valued at $128,065 in the last quarter. Corporate insiders own 1.30% of the company's stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.